Amongst clinical users, 96% were satisfied with our solutions’ ease of use.1
Learn how you can guide PCI with coronary physiology by using clinically validated indices: instant wave-Free Ratio (iFR) or fractional flow reserve (FFR).
Effective, efficient treatment in coronary artery disease. Access clinical insights and increase confidence in treatment while reducing procedure time.
[1] D434401. Evaluated with clinical users in a simulated environment.
[2] Hennessey B. et al. Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention, 2024;20:e198-e206
[3] These results were obtained during an independent survey performed between July and December 2022. The survey involved 38 participants from 6 countries spread over technologist, nurses and physicians. Questions were asked to participants that had relevant working experience in both a Philips Integrated Coronary Suite (combination of Azurion, IntraSight and Philips Hemo, Eagle Eye, Refinity and OmniWire) and a multi-vendor coronary cath lab (A multi-vendor lab is a cath lab where the equipment needed to perform the procedures is not supplied by a single vendor). The main objective was to evaluate the benefits of a Philips Integrated Coronary Suite compared to a multi-vendor lab.
Always read the label and follow the directions for use.Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device.Products subject to country availability. Please contact your local sales representative.©2024 Koniklijke Philips N.V. All rights reserved. Trademarks are the property of Koninklijke Philips N.V. or their respective owners. Philips reserves the right to change product specifications without prior notification.
You are about to visit a Philips global content page
ContinueThe information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).
By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.